The James Buchanan Brady Urological Institute
 
 
 
H. Ballentine Carter, M.D. H. Ballentine Carter, M.D.
Professor of Urology, Oncology
Johns Hopkins Medicine
Director, Division of Adult Urology
Brady Urological Institute
 Free Access to abstracts at PubMed

  
Journal Articles

JOURNAL ARTICLES

  1. Gold JP, Canizaro P, Kazam E, Carter HB, Kuchta N, and Shires GT. The reliability of the results of ultrasound detection of fluid collection in the early postceliotomy period. Surgery, Gynecology and Obstetrics, 161: 5-8, 1985.


  2. Carter HB, Riehle RA, Jr., Koizumi JH, Amberson J, and Vaughan ED, Jr. Fine needle aspiration of the abnormal prostate: A cytohistologic correlation. J Urol, 135: 294-298, 1986.


  3. Carter HB, Naslund EB, and Riehle RA, Jr. Variables influencing radiation exposure during extracorporeal shock wave lithotripsy: A review of 298 treatments. Urology, 30(6): 546-550, 1987.


  4. Riehle RA, Jr, Carter HB, and Vaughan ED, Jr. Quantitative and crystallographic analysis of voided stone fragments after ESWL. J Endourology, 1(1): 37-44, 1987.


  5. Carter HB, Amberson J, Bander NH, Badalament R, Gorelick J, Vaughan ED, Jr., and Whitmore WF, Jr. Newer diagnostic techniques for bladder cancer. Urologic Clinics of North America, 14(4): 763-769, 1987.


  6. Carter HB and Coffey DS.  Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. J Urol, 140: 173, 1988.


  7. Carter HB and Isaacs JT. Experimental and theoretical basis for hormonal treatment of prostatic cancer. Seminars in Urology, Vol. 6 (4):262-268, 1988.


  8. Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, and Walsh PC. Evaluation of transrectal ultrasound in the diagnosis of prostate cancer. J Urol, 142: 1008-1010, 1989.


  9. Carter HB, Partin AW, and Coffey DS. Prediction of metastatic potential in an animal model of prostate cancer: Flow cytometric quantification of cell surface charge. J Urol, 142:1338-1341, 1989.


  10. Carter HB and Isaacs JT. Why do cells metastasize? World J Urol, 8: 2-5, 1990.


  11. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh P.C. Prostate-Specific Antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol, 143: 747-752, 1990.


  12. Carter HB, Piantadosi S, and Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol, 143: 742-746, 1990.


  13. Carter HB, Partin AW, Epstein JI, and Walsh PC. Relationship between PSA and residual tumor volume in stage A prostate cancer. J Urol, 144: 1167-1171, 1990.


  14. Carter HB and Coffey DS. The prostate: An Increasing medical problem. Prostate, 16: 39-48, 1990.


  15. Carter BS, Carter HB, and Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate, 16: 187-197, 1990.


  16. Epstein JI, Christensen WN, Steinberg GD, Carter HB, and Walsh PC. Comparison of DNA ploidy and nuclear size, shape, and chromatin irregularity in tissue sections and smears of prostatic carcinoma. Analytical and Quantitative Cytology and Histology, 12(5): 352-358, 1990.


  17. Carter HB, Brem RF, Tempany CM, Yang A, Epstein JI, Zerhouni EA, and Walsh PC. Nonpalpable prostate cancer: Detection with MR Imaging. Radiology, 178: 523-525, 1991.


  18. Larsen MP, Carter HB, and Epstein JI. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, percent or grade? Study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease. J Urol, 146: 1059-1063, 1991.


  19. Epstein JI, Pizov G, Steinberg GD, Carter HB, Pitcock R, Armas OA, Partin A, and Walsh PC. Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathologic stage at radical prostatectomy. J Urol, 148: 87-91, 1992.


  20. Carter HB, Pearson JD, Metter JE, Brant L J, Chan DW, Andres R, Fozard JL, and Walsh PC. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA, 267: 2215-2220, 1992.


  21. Carter HB, Morrell CH, Pearson JD, Plato, CC, Metter EJ, Chan DW, Fozard JL, and Walsh PC. Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate disease. Cancer Res, 52: 3323-3328, 1992.


  22. Steiner MS, Burnett AL, Brooks JD, Brendler CB, Stutzman RE, and Carter HB. Tubularized neourethra following radical retropubic prostatectomy. J Urol, 150:407-410, 1993.


  23. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, and Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol, 150:110-114, 1993.


  24. Ronnett BM, CarMichael MJ, Carter HB, and Epstein JI. Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol, 150:386-389, 1993.


  25. Carter HB and Pearson JD. PSA velocity: A new concept for the diagnosis of early prostate cancer. Urologic Clinics of North America, 20(4): 665-670, 1993.


  26. Carter HB. Early Detection Of Prostate Cancer: Another View. Primary Care and Cancer, 13: 34-36, 1993.


  27. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, and Walsh PC. Evaluation of serum prostatic specific antigen velocity after radical prostatectomy to distinguish local recurrence versus distant metastases. Urology, 43: 649-659, 1994.


  28. Partin AW, Criley SR, Steiner MS, Hsieh K, Simons JW, Lumadue J, Carter HB, and Marshall FF. Serum ferritin as a clinical marker for renal cell carcinoma: Influence of tumor volume. Urology, 45:211-217, 1995.


  29. Cadeddu JA, Pearson JD, Partin AW, Epstein JI, and Carter HB. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology, 42: 383-389, 1993.


  30. Carter HB and Pearson JD. Evaluation of changes in PSA in the management of men with prostate cancer. Seminars In Oncology 21:554-559, 1994.


  31. Pearson JD and Carter HB. Natural history of changes in prostate-specific antigen in early-stage prostate cancer. J Urol, 152:1743-1748, 1994.


  32. Pearson JD, Morrell CH, Landis PK, Carter HB, and Brant LJ. Mixed-effects regression models for studying the natural history of prostate disease. Stat Med, 13:587-601, 1994.


  33. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL, Rosner W, and Walsh PC. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate, 27:25-31, 1995.


  34. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, and Walsh PC. Prostate-specific antigen variability in men without prostate cancer: The effect of sampling interval and number of repeat measurements on prostate-specific antigen velocity. Urology, 45:591-596, 1995.


  35. Caddedu JA, Pearson JD, Lee BJ, Landis P, Partin AW, Epstein JI, and Carter HB. Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia. Urology, 45:795-800, 1995.


  36. Morrell CH, Pearson JD, Carter HB, Brant LJ. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. J Amer Stat Ass, 90:45-53, 1995.


  37. Schoenberg MP, Carter HB, and Epstein JI. Ureteral frozen section analysis during cystectomy: Reassessment. J Urol, 155:1218-1220, 1996.


  38. Partin AW, Piantadosi S, Subong ENP, Kelly CA, Hortopan S, Chan DW, Wolfert RL, Rittenhouse HG, and Carter HB. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate, 7:35-39, 1996.


  39. Pannek J, Subong ENP, Jones KA, Marschke PLS, Epstein JI, Chan DW, Carter HB, Luderer AA, and Partin AW. The role of free/total PSA in the prediction of final pathological stage for men with clinically localized prostate cancer. Urology, 48(6A):51-54, 1996.


  40. Pearson JD, Luderer AA, Metter EJ, Partin AW, Chan DW, Fozard JL, and Carter HB. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology, 48(6A): 4-9, 1996.


  41. Thiel RP, Oesterling JE, Wojno KJ, Partin AW, Chan DW, Carter HB, Stamey TA, Prestigiacomo AR, Brawer MK, Petteway JC, Carlson G, and Luderer AA. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology, 48(6A):45-50, 1996.


  42. Partin AW and Carter HB. The use of prostate specific antigen and free/total prostate specific antigen in the diagnosis of localized prostate cancer. Urologic Clinics of North America, 23:531-540, 1996.


  43. Thiel R, Pearson JD, Epstein JI, Walsh PC, and Carter HB. The role of prostate specific antigen velocity in prediction of final pathological stage in men with localized prostate cancer. Urology, 49:716-720, 1997.


  44. Carter HB, Partin AW, Luderer A, Metter EJ, Landis T, Chan DW, Fozard JL , and Pearson JD. Percentage of free prostate specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology, 49:379-384, 1997.


  45. Carter HB, Sauvageot J, Walsh PC, and Epstein JI. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol, 157:2206-2209, 1997.


  46. Epstein JI, Walsh PC, Sauvageot J, and Carter HB. Utility of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol, 158:1886-1890, 1997.


  47. Carter HB, Epstein JI, Chan DW, Fozard JL, and Pearson JD. Recommended prostate-specific antigen testing intervals for detection of curable prostate cancer. JAMA, 277:1456-1460, 1997.


  48. Carter HB and Pearson JD. PSA Velocity And Repeated Measures Of PSA. Urologic Clinics of North America 24:333-338, 1997.


  49. Silver RI, Partin AW, Epstein JI, Chan DW, Carter HB, Jeffs RD, and Gearhart JP. Prostate-specific antigen in men born with bladder exstrophy. Urology, 49:253-256, 1997.


  50. Carter HB and Epstein JI. Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate. W J Urol, 15:359-363, 1997.


  51. Carter HB. Nonpalpable prostate cancer detected in the prostate-specific antigen era. W J Urol, 15:239-330, 1997.


  52. Guess HA, Pearson JD, Carter HB, Brant LJ, and Fozard JI. Receiver operating curves for subjects with a previously normal test- Example: prostate specific antigen testing. Journal of Epidemiology and Biostatistics, 2:161-169, 1997.


  53. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB. Nonpalpable (stage T1c) prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160: 2407-2411, 1998.


  54. Argani P, Carter HB, and Epstein JI. Isolated vasculitis of the seminal vesicle. Urology, 52:131-133, 1998.


  55. Carter HB, Lanids PK, Metter E J, Fleisher LA, Pearson JD. Prostate Specific Antigen (PSA) Testing Of Older Men. JNCI 91(20):1733-1737, 1999.


  56. Carter HB, Epstein JI, and Partin AW. The influence of age and prostate specific antigen on the chance of curable prostate cancer among men with non-palpable disease. Urology, 53:126-130, 1999.


  57. Epstein JI, Walsh PC, Akingba G, Carter HB. The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. J Urol, 162:1649-52, 1999.


  58. Williams AM, Simon I, Landis PK, Moser C, Christens-Barry W, Carter HB, Metter EJ, and Partin AW. Prostatic growth rate determined from MRI data: Age-related longitudinal changes. J Androl, 20:474-480, 1999.


  59. Simons JW, Mikhak B, Chang J-F, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete GM-CSF using ex-vivo gene transfer. Cancer Res 59:5160-8, 1999.


  60. Carter HB, Pearson JD. Prostate Specific Antigen (PSA) Testing For Early Diagnosis of Prostate Cancer: Formulation of Guidelines. Urology 54: 780-786, 1999.


  61. Epstein JI, Lecksell K, Carter HB. Prostate cancer sampled on sextant needle biopsy: Significance of cancer on multiple cores from different areas of the prostate. Urology 54:291-294,1999.


  62. Carter HB. A PSA threshold of 4.0ng/mL for early detection of prostate cancer: The only rational approach for men age 50 years and above. Urology 55(6):796-799, 2000.


  63. Harman SM, Metter EJ, Blackman MR, Landis PK, and Carter HB. Insulin like growth factors and binding proteins do not improve prediction of prostate cancer when prostate specific antigen level is known. J Clin Endocrinol Metab 85: 4258-4265, 2000.


  64. Ross K, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate specific antigen screening strategies for prostate cancer detection. JAMA 284: 1399-1405, 2000.


  65. Goldschlag B, Afzal N, Carter HB, Fleisher LA. Is predonation of autologous blood rational for radical retropubic prostatectomy? J Urol 164:1968-72, 2000.


  66. Feneley MR, Landis P, Simon I, Metter EJ, Morrell CH, Carter HB, Walsh PC. Today men with prostate cancer have larger prostates. Urology 56:839-842, 2000.


  67. Potter SR, Carter HB. The role of prostate-specific antigen velocity in prostate cancer early detection. Curr Urol Rep 1:15-9, 2000.


  68. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000; 46 Suppl:S67-72.


  69. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 166:1688-1691, 2001.


  70. Epstein JI, Walsh PC, Carter HB. The importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 57:1112-1116, 2001.


  71. Carter HB. Rationale for earlier and less frequent PSA testing. Urology 58:639-641, 2001.


  72. Wu CL, Carter HB, Naqibuddin M, Fleisher LA. Effect of local anesthetics on patient recovery after transrectal biopsy.  Urology 57:925-929, 2001.


  73. Parsons JK, Schoenberg MS, Carter HB. Incidental renal tumors: Casting doubt on the efficacy of early intervention. Urology 57:1013-1015, 2001.


  74. Carter HB, Landis PK, Epstein JI, Walsh PC. Expectant management of prostate cancer with curative intent. Eur Urol 39 Suppl 4:24, 2001.


  75. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB. Plasma Selenium Level Before Diagnosis and the Risk of Prostate Cancer Development. J Urol 166:2034-2038, 2001.


  76. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate specific antigen (PSA) predict the long term risk of prostate cancer: Results from the Baltimore Longitudinal Study of Aging. Urology 58:411-6, 2001.


  77. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of stage T1c prostate cancer with curative intent: Preliminary results. J Urol 167:1231-1234, 2002.


  78. Wright EJ, Fang J, Metter EJ, Partin AW, Landis PK, Chan DW, Carter HB. Prostate Specific Antigen Predicts The Long-Term Risk Of Prostate Enlargement: Results From The Baltimore Longitudinal Study of Aging. J Urol 167:2484-2488, 2002.


  79. Fang J, Metter EJ, Landis P, Carter HB. PSA Velocity for assessing prostate cancer risk in men with PSA levels between 2.0-4.0ng/mL. Urology 59: 889-894, 2002.


  80. Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ, Platz EA. Calcium intake and prostate cancer risk in a long-term aging study: The Baltimore Longitudinal Study of Aging. Urology 60:1118-1123, 2002.


  81. Brant LJ, Sheng SL, Morrell CH, Verbeke GN, Lesaffre E, Carter HB. Screening for prostate cancer using random-effects models. J R Statist Soc A 166:51-62, 2003.


  82. Carter HB. Informed consent for prostate-specific antigen screening. Urology 61:13-14, 2003.


  83. Hsieh LJ, Carter HB, Landis PK, Tucker KL, Metter EJ, Newschaffer CJ, Platz EA. Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). Urology 61:297-301, 2003.


  84. Khan MA, Partin AW, Carter HB. Expectant Management of Localized Prostate Cancer. Urology 62:793-799, 2003.


  85. Bhasin S, Singh AB, Phong Mac R, Carter HB, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for standardized monitoring plan. J Andrology 24:299-311, 2003.


  86. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, Partin AW, Veltri RW. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 170: 2274-8, 2003.


  87. Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, Carter HB, Platz EA. Association of Prostate Cancer Risk with Insulin, Glucose, and Anthropometry in the Baltimore Longitudinal Study of Aging. Urology 63:253-258, 2004.


  88. Carter HB, Metter EJ, Wright J, Landis P, Platz EA, Walsh PC. Prostate specific antigen and all cause mortality: Results from the Baltimore Longitudinal Study of Aging. JNCI 96:557-558, 2004.


  89. Carter HB. Prostate Cancers in Men with Low PSA Levels — Must We Find Them? N Engl J Med 350:2292-2294, 2004.


  90. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomic extent of lymph node dissection: Impact on men with clinically localized prostate cancer. J Urol 172:1840-4, 2004.


  91. Carter HB, Isaacs WB. Improved Biomarkers For Prostate Cancer: A Definite Need. JNCI 96:813-814, 2004.


  92. Allaf ME, Carter HB. Update on watchful waiting for prostate cancer.  Curr Opin Urol 2004;14:171-5.


  93. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, and Carter HB. Nonsteroidal Anti-inflammatory Drugs and Risk of Prostate Cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005; 14:390-396.


  94. Hernandez DJ, Epstein JI, Trock BJ, Tsuzuki T, Carter HB, Walsh PC. Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? J Urol 2005; 173:446-9.


  95. Ross KS, Guess HA, Carter HB. Estimation of Treatment Benefits When PSA Screening for Prostate Cancer is Discontinued at Different Ages. Urology 66:1038-42, 2005.


  96. Carter HB, Landis P, Wright EJ, Parsons JK, Metter EJ. Can a Baseline PSA Level Identify Men Who Will Develop Lower Urinary Tract Symptoms Later in Life? J Urol 173:2040-3, 2005.


  97. Haffner MC, Landis PD, Saigal CS, Carter HB, Freedland SJ. Health related quality of life outcomes after anatomic retropubic radical prostatectomy in the PDE 5 era: Impact of neurovascular bundle preservation. Urology 2005; 66:371-6.


  98. Berndt SI, Carter HB, Landis PK, Hallfrisch J, Rohrmann S, Metter EJ, Platz EA. Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer. Nutrition 21:686-90, 2005.


  99. Freedland SJ, Haffner MC, Landis PK, Saigal CS, Carter HB. Obesity Does Not Adversely Affect Health-Related Quality-of-Life Outcomes After Anatomic Retropubic Radical Prostatectomy. Urology 2005; 65:1131-6.


  100. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005; 66:356-60.


  101. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Pathological outcomes are similar for men in an expectant management program undergoing delayed surgical intervention compared to those undergoing immediate intervention. J Natl Cancer Inst 2006; 98:355-7.


  102. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ. Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability J Natl Cancer Inst 2006; 98:1521 – 7.


  103. Richman JM, Carter HB, Hanna MN, Murphy JD, Rowlingson AJ, Andrews RAF, Wu CL. Efficacy of Periprostatic Local Anesthetic for Prostate Biopsy Analgesia: a Meta-analysis. Urology 2006; 67:1224-8.


  104. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005; 14:2257-60.


  105. Warlick CA, Allaf ME, Carter HB. Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy. Urol Oncol 2006; 24:51-7.


  106. Carter, HB. Assessing risk: Does this patient have prostate cancer? JNCI 2006; 98:506-7.


  107. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA. Metabolic Factors Associated with Benign Prostatic Hyperplasia. J Clin Endocrinol Metabol 2006; 91:2562-8.


  108. Makarov DV, Carter HB. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol 2006; 176: 2383-5.


  109. Allaf ME, Partin AW, Carter HB. The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. Rev Urol 2006; 8:112-9.


  110. Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ. PSA Velocity Risk Count Assessment: A New Concept for Detection of Life Threatening Prostate Cancer During a Window Of Curability. Urology 2007; 70:685-690.


  111. Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ. Prostate Specific Antigen Doubling Time Does Not Indicate The Presence of High Risk Prostate Cancer at an Early State in Untreated Men: Data From The Baltimore Longitudinal Study of Aging. Submitted to Eur Urol 2007.


  112. Berndt SI, Carter HB, Schoenberg MP, Newschaffer CJ. Disparities in Treatment and Outcome for Renal Cell Cancer among Older Black and White Patients. J Clin Oncol 2007; 25:3589-95


  113. Magheli A, Rais-Bahrami S, Carter HB, Peck HJ, Epstein JI, Gonzalgo ML. Subclassification of Clinical Stage T1 Prostate Cancer: Impact on Biochemical Recurrence Following Radical Prostatectomy. J Urol 2007; 178:1277-1281.

  114. Gonzalgo ML, Carter HB. Update on PSA testing. J Natl Compr Canc Netw 2007; 5:737-42.


  115. Kawachi MH, Bahnson RR, Barry M, et al. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 5:714-36.


  116. Wong R, Carter HB, Wolfson A, Faustin C, Cohen S, Wu C. Use of spinal anesthesia does not reduce intraoperative blood loss. Urology 2007; 70:523-6.


  117. Keller ET, Rowley DR, Tomlins SA, et al. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res 2007; 67:9613-5.


  118. Schröder F, Carter HB, Wolters T, van den Bergh R, Gosselaar C, Bangma C, Roobol M. Early Detection of Prostate Cancer in 2007 Part 1: PSA and PSA Kinetics. Eur Urol 2008; 53(3):468-77


  119. Sheridan TB, Carter HB, Wang W, Landis PB, Epstein JI. Change in Prostate Cancer Grade Over Time in Men Followed Expectantly for Stage T1c Disease. J Urol 2008.


  120. Makarov DV, Marlow C, Epstein JI, Miller MC, Landis P, Partin AW, Carter HB, Veltri RW. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate 2008


  121. Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100:170-183.


  122. Berkowitz J, Carter HB, Gearhart JP. Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes. Urology 2008; 71:1064-6.


  123. Osunkoya AO, Carter HB, Epstein JI. A clinicopathologic study of preoperative and postoperative findings with minute Gleason 3+3=6 cancer at radical prostatectomy. Urology 2008; 72:638-40.


  124. Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB. PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008; 54:1073-80


  125. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Does Prostate Growth Confound Prostate Specific Antigen Velocity? Data From the Baltimore Longitudinal Study of Aging. J Urol 2008; 180:1314-7.


  126. Roddam AW, Allen NE, Appleby P et al. Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. Ann Intern Med 2008; 149:461-471.


  127. Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ and Metter EJ. Prostate specific antigen testing among the elderly--when to stop? J Urol 2009; 181:1606-14.


  128. Loeb S, Schaeffer EM, Chan DW, Carter HB, Walsh PC, Sokoll LJ. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology 2009; 73:947-9.


  129. Kramer BS, Hagerty KL, Justman S, et al. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009; 181:1642-57.


  130. Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, Metter EJ. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol 2009; 182:101-4.


  131. Bastian PJ, Carter HB, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F. Insignificant prostate cancer and active surveillance: From definition to clinical implications. Eur Urol 2009; 55:1321-1332.


  132. Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW. Pro-Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer. Clinical Cancer Research Clin Cancer Res  2009 15:7316-21.


  133. Loeb S, Carter HB. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. Urol Oncol 2009; 27:583-4.


  134. Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, Metter EJ. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol 2009; 182:2646-51.


  135. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182:2232-41.


  136. Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009; 182:2274-8.


  137. Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int 2010; 105:824-9.


  138. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging.  J Urol 2009; 182:1458-62.


  139. Isharwal S, Makarov DV, Carter HB, Epstein JI, Partin AW, Landis P, Marlow C, Veltri RW. DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme. BJU Int 2010; 105:329-33


  140. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, Sokoll LJ. Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. J Urol 2010; 183:534-8.


  141. Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010; 183:1779-85.


  142. Kawachi MH, Bahnson RR, Barry M, et al. NCCN clinical practice guidelines in oncology: Prostate cancer early detection. J Natl Compr Canc Netw 2010; 8:240-62.


  143. Loeb S, Carter HB, Schaeffer EM, Ling SM, Kettermann A, Ferrucci L, Metter EJ. Bone mineral content and prostate cancer risk: Data from the Baltimore Longitudinal Study of Aging. BJU Int 2010; 106:28-31.


  144. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28:2810-6.


  145. Kettermann AE, Ferrucci L, Trock BJ, Metter EJ, Loeb S, Carter HB. Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer. BJU Int 2010; 106:1284-90.


  146. Isharwal S, Makarov DV, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW. ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program. Urology 2011; 77:763.e1-6.


  147. Loeb S, Carter HB, Schaeffer EM, Kettermann A, Ferrucci L, Metter EJ. Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. Urology 2011; 77:143-7.


  148. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What Is the True Number Needed to Screen and Treat to Save a Life With Prostate-Specific Antigen Testing? J Clin Oncol 2011; 29: 464-7.


  149. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB. Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. J Clin Oncol 2011; 29:2185-90.


  150. Tseng KS, Landis P, Brimo F, Partin AW, Epstein JI, Carter HB. Repeat prostate biopsies predict location of index cancer in an active surveillance cohort. BJU Int. 2011; 108:1415-20.


  151. Al-Hussain T, Carter HB, Epstein JI. Significance of Prostate Adenocarcinoma Perineural Invasion on Biopsy in Patients Who are Otherwise Candidates for Active Surveillance. J Urol 2011; 186:470-473.


  152. Loeb S, Carter HB. Should prostate-specific antigen velocity be abandoned? Asian J Androl 2011; 13:359-60.


  153. Ko JS, Landis P, Carter HB, Partin AW. Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants. BJU Int 2011; 108:1739-42


  154. Nichols JH, Loeb S, Metter EJ, Ferrucci L, Carter HB. The relationship between prostate volume and prostate-specific antigen variability: data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program. BJU Int 2011 [Epub ahead of print]


  155. Carter HB. Management of low (favourable)-risk prostate cancer BJU Int 2011; 108:1684-95.


  156. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186:1830-4.


  157. Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH. Baseline prostate-specific antigen testing at a young age. Eur Urol 2012; 61:1


  158. Liu D, Lehmann HP, Frick KD, Carter HB. Active surveillance versus surgery for low risk prostate cancer: A clinical decision analysis. J Urol 2012; 187:1241-6.


  159. Ross AE, Feng Z, Pierorazio PM, Landis P, Wash PC, Carter HB, Trock BJ, Schaeffer EM. Effect of treatment with 5-alpha reductase inhibitors on progression in monitored men with favorable-risk prostate cancer. BJU Int 2012 (Epub ahead of print)


  160. Dall'era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active Surveillance for Prostate Cancer: A Systematic Review of the Literature. Eur Urol 2012 Jun 7. [Epub ahead of print]


  161. Pollack CE, Noronha G, Green GE, Bhavsar NA, Carter HB. Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. Arch Intern Med 2012; 172:668-70.


  162. Getzenberg RH, Carter HB. Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer. Asian J Androl 2012; 14:347-8.


  163. Pollack CE, Platz EA, Bhavsar NA, Noronha G, Green GE, Chen S, Carter HB. Primary care providers' perspectives on discontinuing prostate cancer screening. Cancer. 2012 [Epub ahead of print]


  164. Mullins JK, Han M, Pierorazio PM, Partin AW, Carter HB. Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol 2012; 187:1620-5.


  165. Carter HB. Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl 2012; 14:355-60.


  166. Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ. Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer. J Urol 2012; 188:1131-6.


  167. Han JS, Toll AD, Amin A, Carter HB, Landis P, Lee S, Epstein JI. Low Prostate-specific Antigen and No Gleason Score Upgrade Despite More Extensive Cancer During Active Surveillance Predicts Insignificant Prostate Cancer at Radical Prostatectomy. Urology 2012; 80:883-8.


  168. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R.  Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy. Clin Cancer Res 2012; 18:5471-5478.


  169. Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI. Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer? J Clin Oncol. 2012 Oct 1. [Epub ahead of print]


  170. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol. 2012 Oct 9. pii: S0022-5347(12)05184-1. doi: 10.1016/j.juro.2012.10.005. [Epub ahead of print]

TEXTBOOK CHAPTERS
  1. Carter HB and Coffey DS. Prostate Cancer: The magnitude of the problem in the United States. In: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Edited by Donald S Coffey, Martin I Resnick, F Andrew Dorr, and James P Karr. New York: Plenum Press, pp. 1-7, 1988.

  2.  Carter HB and Coffey DS. Prediction of tumor behavior in prostate cancer. In:  Prostate Cancer: The Second Tokyo Symposium. Edited by James P Karr and Hidetoshi Yamanaka. New York: Elsevier, pp. 19-27, 1989.

  3.  Coffey DS and Carter HB. New Frontiers In The Treatment of Prostatic Cancer. In: Current Trends and Controversies: The Treatment of Prostatic Cancer. MES Medical Education Services, pp 2-3, 1989.

  4.  Coffey DS and Carter HB. Advanced Prostatic Cancer. In: Current Trends and Controversies: The Treatment of Prostatic Cancer. MES Medical Education Services, pp. 32-33, 1989.

  5.  Carter HB, Partin AW, Oesterling JE, Weber JP, Epstein JI, Chan DW, Rock RC, and Walsh P.C. The use of prostate specific antigen in the management of patients with prostate cancer: The Johns Hopkins Experience. In: Clinical Aspects Of Prostate Cancer: Assessment Of New Diagnostic And Management Procedures.  Edited by William J Catalona, Donald S Coffey, and James P Karr.  New York: Elsevier, pp. 247-251, 1989.

  6.  Carter HB and Isaacs JT. Prostate cancer: Past, present and future. In: Prostate Cancer: Diagnosis and Therapy.  Edited by G Staehler and PG Fabricius.  Berlin: Springer-Verlag, pp. 1-8, 1990.

  7.  Carter HB and Isaacs JT. Overview of hormonal therapy for prostate cancer. In:  Progress In Clinical And Biological Research, Vol. 350. Edited by Hubert G Frohmuller and Manfred P Wirth. New York: Wiley-Liss, Inc., pp. 129-140, 1990.

  8.  Pearson JD, Kaminski P, Morrell CH, Carter HB, Metter EJ, Fozard JL, and Brant LJ. Modeling longitudinal rates of change in prostate specific antigen during aging. In: Proceedings of the American Statistical Association Meetings: Social Statistics Section. Alexandria, Va, American Statistical Association; pp. 580-585, 1991.

  9.  Carter HB and Walsh PC. Stage A1 prostatic adenocarcinoma. In: Current Therapy In Genitourinary Surgery (2nd edition). Edited by Martin I Resnick and Elroy D Kursh.. Toronto: BC. Decker Inc, pp. 103-105, 1992.

  10.  Partin AW, Carter HB, Epstein JI, and Coffey DS. The Biology Of Prostate Cancer: New And Future
    Directions In Predicting Tumor Behavior. In: Pathology And Pathobiology Of The Urinary Bladder And Prostate. Edited by Ronald S Weinstein and William A Gardner, Jr. Baltimore: Williams and Wilkins, pp. 198-218, 1992.

  11.  Carter HB. Evaluation Of The Urologic Patient: Instrumentation And Endoscopy. In: Campbell's Urology (6th edition). Edited by Patrick C Walsh, Alan B Retik, Thomas A Stamey and E Darracott Vaughan. Philadelphia: WB Saunders Co, pp. 331-341, 1992.

  12.  Carter HB. Current Status Of PSA In The Management Of Prostate Cancer. In: Advances In Surgery (Vol 27). Edited by John L Cameron. Chicago: Mosby-Year Book Inc, pp. 81-95, 1994.

  13.  Carter HB. Ureterolithotomy. In: Operative Urology (2nd edition). Edited by Fray F Marshall. Philadelphia: WB Saunders Co, pp. 352-355, 1996.

  14.  Partin AW and Carter HB. Prostate-specific antigen: Use of PSA Density and PSA Velocity. In: Comprrehensive Textbook of Genitourinary Oncology. Edited by Nicholas J Vogelzang, Peter T Scardino, William U Shipley and Donald S Coffey. Baltimore: Williams and Wilkins, pp. 680-684, 1996.

  15.  Carter HB and Pearson JD. PSA and the natural course of prostate cancer. In: Recent advances in prostate cancer and BPH. Edited by Fritz H Schroder. New York: Parthenon Publishing Group, pp. 187-193, 1997.

  16.  Carter HB and Partin AW. Can progression of prostate cancer be predicted by pre-treatment parameters. In: Recent advances in prostate cancer and BPH. Edited by Fritz H Schroder. New York: Parthenon Publishing Group, pp. 215-224, 1997.

  17.  Carter HB. Evaluation Of The Urologic Patient: Instrumentation And Endoscopy. In: Campbell's Urology (7th edition). Edited by Patrick C Walsh, Alan B Retik, Alan J Wein  and E Darracott Vaughan, Jr. Philadelphia: WB Saunders Co, pp.159-169, 1998.

  18.  Carter HB and Partin AW. Diagnosis and Staging of  Prostate Cancer. In: Campbell'sUrology (7th edition). Edited by Patrick C Walsh, Alan B Retik, Alan J Wein and E Darracott Vaughan, Jr. Philadelphia: WB Saunders Co, pp. 2519-2537, 1998.

  19.  Brendler CB and Carter HB. Urological Cancers. In: The Principles and Practice of Medicine, 23rd Edition. Edited by John D Stobo, Thomas A Traill, David B Hellmann, Paul W Ladenson, Brent G Petty. Norwalk: Appleton and Lange, Inc, pp. 790-796, 1996.

  20.  Carter HB and Walsh PC. The epidemiology of prostate cancer in Jamaicans. In: Advanced Therapy of Prostatic Disease. Edited by Martin I Resnick and Ian M Thompson: BC Decker, Inc, pp. 28-30, 2000.

  21.  Carter HB. Evidence-Based Surgery: Urology. In: Evidence-Based Surgery. Edited by Toby A Gordon and John L Cameron: BC Decker, Inc, pp. 617-627, 2000.

  22.  Rodriguez R and Carter HB. The current management of carcinoma of the prostate. In: Advances In Surgery (Vol 28). Edited by John L Cameron. Chicago: Mosby-Year Book Inc, 33:181-97, 1999.

  23.  Schoenberg MP and Carter HB. Urological Cancers. In: The Principles and Practice of Medicine, 24th Edition. Edited by John D Stobo, Thomas A Traill, David B Hellmann, Paul W Ladenson, Brent G Petty. Norwalk: Appleton and Lange, Inc, (in press).

  24.  Chan DY and Carter HB. Urologic Complications. In: Advanced Therapy of Inflammatory Bowel Disease, 2nd Edition. Edited by Theodore M Bayless and Stephen B Hanauer. Ontario: BC Decker, Inc, pp. 321-323, 2001.

  25.  Denis L, Mettlin C, Carter HB, De Koning HJ, Fourcade R, Fournier G, Hugosson J, Koroltchouk V, Moul R, Stephenson R. Early detection and screening. In: Prostate Cancer: 2nd International Consultation on Prostate Cancer 1999. Edited by G Murphy, S Khoury, A Partin, L Denis. Plymouth, United Kingdom: Plymbridge Ltd, pp. 219-234, 2000.

  26.  Carter HB. Basic Instrumentation and Cystoscopy. In: Campbell's Urology (8th edition). Edited by Patrick C Walsh, Alan B Retik, Alan J Wein  and E Darracott Vaughan, Jr. Philadelphia: WB Saunders Co, pp.111-119, 2002.

  27.  Carter HB and Partin AW. Diagnosis and Staging of Prostate Cancer. In: Campbell'sUrology (8th edition). Edited by Patrick C Walsh, Alan B Retik, Alan J Wein and E Darracott Vaughan, Jr. Philadelphia: WB Saunders Co, pp. 3055-3064, 2002.

  28.  Nelson WG, Carter HB, DeWeese TL, Bajaj G, Thompson TL, Eisenberger MA. Prostate Cancer. In: Clinical Oncology (3rd edition). Edited by Martin D Abeloff, James O Armitage, John E Niederhuber, Michael B Kastan and W Gillies McKenna. Philadelphia: Elsevier Churchill Livingstone, pp.2085-2148, 2004.

  29.  Carter HB. Postprostatectomy Radiotherapy (commentary). In: Management of Prostate Cancer: Advances and Controversies. Edited by Kenneth B Cummings. New York: Marcel Dekker, pp. 302-304, 2005.

  30.  Chan D and Carter HB. Basic Instrumentation and Cystoscopy. In: Campbell's Urology (9th edition). Edited by Alan J Wein, Louis R Kavoussi, Andrew C Novick, Alan W Partin, Craig Peters. Philadelphia: WB Saunders Co, pp 171-220, 2007.

  31.  Carter HB, Allaf M, and Partin AW. Diagnosis and Staging of Prostate Cancer. In: Campbell'sUrology (9th edition). Edited by Alan J Wein, Louis R Kavoussi, Andrew C Novick, Alan W Partin, Craig Peters. Philadelphia: WB Saunders Co, pp 2912-2931, 2007.

  32.  Carter HB. The role of prostate-specific antigen velocity in the diagnosis and management of prostate cancer. In: Prostate Biopsy: Indications, Techniques, and Complications. Edited by J Stephen Jones. New Jersey: Humana Press, pp. 61-70, 2008.



INVITED LECTURES AND SPECIAL PRESENTATIONS


  1. The Use of PSA in the Management of Prostate Cancer. National Cancer Institute Conference on Prostate Cancer, Prouts Neck, Maine, October, 1988.


  2. Ureteropyeloscopy: Role in Diagnosis and Therapy of Urologic Disease. Surgical Grand Rounds, Johns Hopkins Hospital, December 9, 1989.


  3. Nonoperative Treatment of BPH. Medical Grand Rounds, Washington Adventist Hospital, April 20, 1990.


  4. The Natural History of Stage A1 Prostate Cancer: The Johns Hopkins Experience. Urologic Oncologic Workshop, Berlin, West Germany, June 9, 1990.

  5. Management of Stage A Prostate Cancer. Current Concepts in Prostate Cancer. Annual Urologic Conference, Thomas Jefferson University, Philadelphia, October 25, 1990.


  6. Surgical Management of Urolithiasis. Topics in Nephrology Conference, Francis Scott Key Hospital, January 29, 1991.


  7. Medical and Surgical Management of Nephrolithiasis. Medical Grand Rounds, Department of Medicine, Johns Hopkins University School of Medicine, March 8, 1991.


  8. Prostatism: Evaluation and Management. Topics In Ambulatory Medicine, Johns Hopkins Hospital, Baltimore, MD, April 10-12, 1991.


  9. Management of Renal Calculi. Topics in Clinical Medicine, Department of Medicine, Johns Hopkins University School of Medicine, May 7, 1991.


  10. Longitudinal Evaluation Of PSA In Men With And Without Prostate Disease. Department Of Urology Grand Rounds, Baylor College Of Medicine, Houston, Texas, July 26, 1991.


  11. New Approaches To The Early Diagnosis of Prostate Cancer: The Value of PSA. Department of Surgery Grand Rounds, Johns Hopkins Hospital, September, 14, 1991.


  12. New Approaches To The Early Diagnosis of Prostate Cancer: The Value of PSA. Department of Medicine Grand Rounds, Johns Hopkins Hospital, September 20, 1991.


  13. Urologic Approach To Renal Stone Disease. Department of Cardiovascular and Interventional Radiology Grand Rounds, Johns Hopkins Hospital, October 23, 1991.


  14. PSA In The Early Diagnosis Of Prostate Cancer. Maryland Urological Meeting, Johns Hopkins Hospital, November 16, 1991.


  15. The Use of PSA in Management of Prostate Cancer. Department of Medicine Grand Rounds, Johns Hopkins Hospital, February 1, 1992.


  16. PSA In The Early Diagnosis of Prostate Cancer. Diagnosis and Treatment of Neoplastic Disorders (18th Annual Symposium); The Johns Hopkins Oncology Centers, April 2-3, 1992.


  17. Rate Of Change In Prostate Specific Antigen: A Novel Approach For The Earlier Detection Of Prostate Cancer. PSA Symposium, American Urological Association annual meeting, Washington, D.C., May 9, 1992.


  18. Screening For Prostate Cancer. Topics In Clinical Medicine, Department of Medicine,  Johns Hopkins Hospital, May 15, 1992.


  19. Advances In Diagnosis And Treatment Of Prostate Cancer. Providence Hospital CME Conference, Washington, D.C., May 28, 1992.


  20. Longitudinal Evaluation of Prostate Specific Antigen Levels In Men With and Without Prostate Disease. Symposium on Benign Prostatic Hyperplasia. Robert Wood Johnson University Hospital, June 12 and 13, 1992.


  21. Prostate Examination: 1992. Topics In Gastroenterology And Liver Disease. Johns Hopkins Hospital, September 30-October 2, 1992.


  22. Longitudinal Studies Of PSA. Molecular Biology And Natural History Of Prostate Cancer Seminar of the National Cancer Institute, Prout's Neck, Maine, October 15-18, 1992.


  23. Screening For Prostate Cancer: Use Of PSA. Texas Club Of Internists, Harbor Court Hotel, Baltimore, Maryland, October 22, 1992.


  24. Screening For Prostate Cancer. Cancer Update For The Primary Care Physician, Centre Community Hospital, State College, PA., October 28, 1992.


  25. Surgery As Treatment Of Early Prostate Cancer. Cancer Update For The Primary Care Physician, Centre Community Hospital, State College, PA., October 28, 1992.


  26. Current Status Of PSA In The Diagnosis And Management Of Prostate Cancer. Roper Cancer Symposium, Charleston, S.C., October 31, 1992.


  27. Longitudinal Evaluation Of Changes In PSA. Roper Cancer Symposium, Charleston, S.C., October 31, 1992.


  28. Prevention of Urinary Tract Calculi. Department of Cardiovascular and Interventional Radiology Grand Rounds, Johns Hopkins Hospital, January 28, 1993.


  29. Identifying Markers For Prostatic Diseases. Consultants Meeting For Benign Prostatic Hyperplasia And Other Chronic Disorders Of Aging, Amelia Island, Florida, February 26, 1993.


  30. Prostate Specific Antigen And Prostate Cancer. Annual Meeting Of American Urological Association, San Antonia, Texas, May 15, 1993.


  31. Prostate Cancer: Early Detection, Evaluation and Surgical Management. Prostate Cancer 1993 (Washington Adventist Hospital Conference), Bethesda, Maryland, November 5, 1993.


  32. Prostate Cancer: Early Detection, Evaluation and Management. 21st Annual Geriatrics Symposium: A Board Review, Baltimore, Maryland, Jan 24-28, 1994.


  33. Update On The Use Of PSA. Surgical Grand Rounds, Johns Hopkins Hospital, February 19, 1994.


  34. The Use Of PSA In Men With Prostate Cancer. Prostate Cancer Symposium, Lenox Hill Hospital, New York, N.Y., September 29, 1994.


  35. Do We Detect Insignificant Prostate Cancer With PSA? International Symposium On Prostate Cancer, Munich, Germany, October 14-15, 1994.


  36. Anatomic Approach To Radical Prostatectomy, International Symposium On Prostate Cancer, Munich, Germany, October 14-15, 1994.


  37. Prostate Cancer: Surgical View. Advances and Controversies in Primary Care Geriatrics, Baltimore Maryland, February 3, 1994.


  38. Screening For Prostate Cancer. Medical Grand Rounds at The Naval Hospital, Bethesda, Maryland, February 16, 1995.


  39. PSA Velocity. Prostate Cancer Controversies, Baylor University Medical Center, Dallas, Texas, March 22, 1996.


  40. PSA in Staging Prostate Cancer. Prostate Cancer Controversies, Baylor University Medical Center, Dallas, Texas, March 22, 1996.


  41. PSA and The Natural Course of Prostate Cancer. Progress and Controversies in Oncological Urology, Rotterdam, Netherlands, April 11-13, 1996.


  42. Can Progression of Prostate Cancer be Predicted by Pre-Treatment Parameters. Progress   and Controversies in Oncological Urology, Rotterdam, Netherlands, April 11-13, 1996.


  43. Evaluation of Men With Stage T1c Prostate Cancer. Grand Rounds Urology, Johns Hopkins Hospital, October 29, 1996.


  44. Early Detection of Prostate Cancer With PSA Screens. Men’s Health Symposium, Baltimore, Maryland, November 11, 1996.


  45. Cancer in the New Millenium. JAMA press conference. New York, N.Y., May 13, 1997.


  46. Non-Palpable Prostate Cancer in the PSA Era. Surgical Ground Rounds at Johns Hopkins Hospital, November 8, 1997, Baltimore, MD.


  47. Watchful Waiting For Men With Non-Palpable Prostate Cancer. Maryland Urological Association, November 22, 1997, Baltimore, MD.


  48. Diagnosis and Management of Prostate Cancer in the PSA Era. Grand Rounds, Naval Hospital, March 12, 1998, Bethesda, MD.


  49. PSA Testing. Grand Rounds, Johns Hopkins Hospital, August 11, 1998, Baltimore, MD.


  50. New Aspects of Prostate Cancer Management, State of the Art Lecture, James C. Kimbrough Urologic Seminar, October 15, 1998, Williamsburg, Virginia.


  51. Prostate Cancer Controversies in the PSA Era. The Bernard Kleiman Symposium on Men’s Health Care. Saturday, February 20, 1999, Baltimore, Maryland.


  52. Prostate Cancer Early Detection: National Comprehensive Cancer Network Guidelines (4th Annual Conference). Saturday, February 26, 1999, Fort Lauderdale, Florida.


  53. Guidelines for Early Detection of Prostate Cancer. Grand Rounds at the Bethesda Naval Hospital, Department of Urology. Thursday, March 11, 1999, Bethesda, MD.


  54. Interpretation and Misinterpretation of a PSA assay. 3rd Annual Men’s Health 1999. Johns Hopkins University, April 9, 1999, Baltimore, MD.


  55. Early Detection of Prostate Cancer. Current Treatment of Prostate Cancer. Mid-Hudson Health Cancer Center, Poughkeepsie, New York, October 20, 1999.


  56. Early Detection of Prostate Cancer and Expectant Management for Localized Disease. Medicine Grand Rounds at the Johns Hopkins Hospital. October 23, 1999.


  57. Comparative efficiency of prostate specific antigen screening strategies for prostate cancer detection. Maryland Urological Meeting, Johns Hopkins Hospital, November 13, 1999.


  58. Prostate Cancer: State of the Art. Renophobia Relief, Johns Hopkins Hospital, November 15, 1999.


  59. PSA Effect on Prostate Cancer Statistics and Evolution of PSA Screening. Urology Grand Rounds, Johns Hopkins Hospital, February 29, 2000.


  60. Management of rising PSA after definitive therapy for prostate cancer. US TOO Public Symposium, Washington DC, June 10, 2000.


  61. Expectant Management of Prostate Cancer. Heinrich Warner Symposium, Hamburg, Germany, November 3, 2000.


  62. Visiting Professor. Epindorff University, Hamburg, Germany, November 2.


  63. Prevention, Diagnosis, and Management of Prostate Cancer. Kronos Foundation. Phoenix, Arizona, February 23, 2001.


  64. Early Diagnosis of Prostate Cancer.  Topics in Clinical Medicine, Johns Hopkins School of Medicine, Baltimore MD, May 10, 2001.


  65. Early Diagnosis of Prostate Cancer. Medicine Grand Rounds. Johns Hopkins School of Medicine, Baltimore MD, Novermber10, 2001.


  66. Rationale for Earlier and Less Frequent PSA Testing. Maryland Urological. Johns Hopkins School of Medicine, Baltimore MD, Novermber10, 2001.


  67. Early Detection of Prostate Cancer. New Perspectives on Prostate Cancer Symposium. Washington Adventist Hospital, November 16, 2001.


  68. Surgical Management of Prostate Cancer. New Perspectives on Prostate Cancer Symposium. Washington Adventist Hospital, November 16, 2001.


  69. Primary and Secondary Prostate Cancer Prevention. Visiting Professor at Center for Prostate Disease Research, Bethesda MD, December 15, 2001.


  70. Prostate Cancer Screening: Rationale and Strategy. Surgical Grand Rounds, Johns Hopkins School of Medicine, September 7, 2002.


  71. Diagnosis and Management of Prostate Cancer in the PSA era. The World Bank, Washington DC, November 20, 2002.


  72. PSA For Early Detection of Prostate Cancer. Multidisciplinary Advances in the Treatment of Prostate Cancer. University of N.C., January 31-February 1, 2003.


  73. Surgery for Clinically Localized Prostate Cancer. Multidisciplinary Advances in the Treatment of Prostate Cancer. University of N.C., January 31-February 1, 2003.


  74. Diagnosis and Management of Prostate Cancer in the PSA Era. Urology Nursing Society, Baltimore MD, April 10-11, 2003.


  75. Problem Cases in Prostate Cancer: Panel Discussion at Annual American Urological Association Meeting. Chicago, Ill, April 30, 2003.


  76. 48th Annual Philip A Tumulty Topics In Clinical Medicine. Diagnosis and Management of Prostate Cancer in the PSA Era. Turner Auditorium, Johns Hopkins School of Medicine, May 8, 2003.


  77. Reconstructive Surgery of the Urogenital Tract: International Symposium With Live Surgery. Performance of radical prostatectomy (Live-Surgery) May 23; Prostate Cancer Screening: Fact and Fiction (Talk) May 24. Department of Urology, University Hospital Grosshadern, Ludwig-Maximillians-University; Munich, Germany, May 23-24, 2003.


  78. Detection and Treatment of Prostate Cancer. South Carolina Urological Association Annual Meeting, Columbia, SC, September 17, 2003.


  79. Prostate Cancer Screening: Personal Views. Invited lecture at Free University Medical Center, Amsterdam Netherlands, October 30, 2003.


  80. Expectant Management of Prostate Cancer With Curative Intent. Maryland Urological Association Meeting. Baltimore MD, November 22, 2003.


  81. Expectant Management of Prostate Cancer With Curative Intent. Engadin Prostate Cancer Symposium. Zuoz, Switzerland, March 3-7, 2004.


  82. Expectant Management of Prostate Cancer With Curative Intent: The Johns Hopkins Experience. Urology Grand Rounds, Johns Hopkins Hospital, April 8, 2004.


  83. An Update on Prostate Cancer. Topics In Clinical Medicine. Johns Hopkins Hospital, May 6, 2004.


  84. Expectant Management of Prostate Cancer With Curative Intent: The Johns Hopkins Experience. Urological Club of Great Britain and Ireland, Annual Meeting. Dublin, Ireland (Guest Speaker), September 16-17, 2004.


  85. Biochemical Recurrence of Prostate Cancer. Mid Atlantic Section of American Urological Association (speaker). Cambridge, MD, October 3-6, 2004.


  86. Update on Prostate Cancer. Topics in Clinical Medicine, Johns Hopkins School of Medicine. May 5, 2005.


  87. Watchful Waiting for Prostate Cancer: Course #861C American Urological Association annual meeting. San Antonio, TX, May 25, 2005.


  88. Surgery or Watchful Waiting for Prostate Cancer. National Conference on Prostate Cancer. Omni Shoreham Hotel, Washington DC, June 17, 2005.


  89. Prostate Cancer Update. Clinical Issues in Primary Care (Pri-Med). Baltimore Convention Center, Baltimore MD, October 6-8, 2005.


  90. Early Detection of Prostate Cancer: How and when do we screen? New Perspectives on Prostate Cancer, Washington Adventist Hospital, Bethesda MD, November 3, 2005.


  91. Prostate Cancer Surgery: Indications and Technique. New Perspectives on Prostate Cancer, Washington Adventist Hospital, Bethesda MD, November 3, 2005.


  92. Expectant Management of Prostate Cancer. Advances in Urology 2005. Emory University School of Medicine. Atlanta, Georgia, December 2-3, 2005.


  93. PSA Kinetics. Advances in Urology 2005. Emory University School of Medicine. Atlanta, Georgia, December 2-3, 2005.


  94. Early Detection of Prostate Cancer: How and when do we screen? Virginia Urological Annual Meeting. Hot Springs, VA, February 10-11, 2006.


  95. Expectant Management of Prostate Cancer. Virginia Urological Annual Meeting. Hot Springs, VA, February 10-11, 2006.


  96. Post Graduate Course on Expectant Management of Prostate Cancer, American Urological Association Annual Meeting, 2005, 2006.


  97. Case Management of Rising PSA after Radiation Therapy or Surgery for Prostate Cancer: Plenary Session of American Urological Association Annual Meeting, Atlanta, Georgia May 23, 2006.


  98. PSA as a Population Screening Test. School of Public Health (LearnLink Series). September 28, 2006.


  99. Expectant Management of Prostate Cancer: Why, Who, How? Prout’s Neck, Maine. NCI conference on “Emerging strategies in prostate cancer therapy”, November 2-5, 2006.


  100. Identification of Life Threatening Prostate Cancer During A Window of Curability. Urology Update 2006. Johns Hopkins, November 11, 2006.


  101. Reducing Over Treatment of Prostate Cancer. Man to Man. Johns Hopkins, March 27, 2007


  102. Diagnosis and Management of Prostate Cancer: Update 2007. 52nd Annual Tumulty Topics in Clinical Medicine. May 10, 2007.


  103. Overtreatment of Prostate Cancer: How Big a Problem. ASCO Annual Meeting (Educational Session). Chicago, IL, June 3, 2007.


  104. Expectant Management of Prostate Cancer. Northeastern Section of AUA. Rochester NY. September 9, 2007.


  105. Prostate cancer screen, early detection and biopsy technique. 14th Annual Cancer Symposium. Bethesda MD, October 2007.


  106. Prostate cancer surgery: update. 14th Annual Cancer Symposium. Bethesda MD, October 2007.


  107. Active observation of low risk prostate cancer. 4th biennial prostate cancer conference. Philadelphia, PA, November 2, 2007.


  108. Prostate cancer screening: Where are we and where should we go? AUA Webinar series. September 24, 2008.


  109. Surveillance for prostate cancer. Panel at Mid Atlantic Section of AUA. Cambridge, MD, September 26, 2008.


  110. Prostate cancer screening. Webinar series for AUA. September 24, 2008.


  111. Prostate cancer risk: Genotype and PSA. Urology Update. Johns Hopkins. November 8, 2008.


  112. Prostate cancer screening: Benefits versus Harms. Longrifles. Johns Hopkins. November 12, 2008.


  113. Active surveillance for low risk prostate cancer: Risky business or rational choice? Longrifles. Johns Hopkins. November 12, 2008.


  114. Prostate cancer: Natural History and Lessons Learned from the BLSA. Cancer intervention and surveillance modeling network (CISNET). Annual meeting in Bethesda, MD, November 19, 2008.


  115. Prostate cancer screening. Maryland American College of Physicians. Ellicott City, MD, February 6, 2009.


  116. Prostate cancer screening: Benefits and Harms. Board of Trustees of Johns Hopkins. May 3, 2009.


  117. Prostate cancer screening: Benefits and Harms. 54th Annual Tumulty Topics in Clinical Medicine. Johns Hopkins School of Medicine. May 4, 2009.


  118. Prostate cancer risk: Genotype and PSA. 123rd  Meeting of the American Association of GU Surgeons. Torrey Pines, California. May 8, 2009.


  119. Prostate cancer: New is better; or is it? Prostate cancer symposium keynote speaker, Suburban Hospital. Bethesda, MD. September 14, 2009.


  120. Prostate cancer surveillance: The North American Experience. ASCO/ECCO. Berlin, Germany. September 23, 2009.


  121. Update on PSA Screening. Medicine Grand Rounds, Harbor Hospital. October 9, 2009.


  122. Emerging Diagnostic and Prognostic Serum Biomarkers and Update on Prostate Cancer Screening. 16th Annual Cancer Symposium. New Perspectives on Prostate Cancer. Bethesda, MD, November 13, 2009.


  123. Active Surveillance for Prostate Cancer. Visiting Professor, University of Pennsylvania Department of Urology. Philadelphia PA, December 3, 2009.


  124. Active Surveillance for Prostate Cancer. International Focal Therapy Symposium. Washington DC, February 26, 2010.


  125. Update of PSA Screening. Topics in Clinical Medicine. Johns Hopkins School of Medicine. Baltimore MD, May 3, 2010.


  126. Debate on Prostate Cancer Surveillance: Society of Urologic Oncology Annual Meeting at American Urological Association Annual Meeting in San Francisco CA, May 29, 2010.


  127. ProActive Surveillance: An Underutilized Approach to Management of Prostate Cancer. Moderator, 17th Annual Prostate Cancer Foundation Meeting, Washington DC, September 14-16.


  128. Reducing the Harms of Prostate Cancer Screening. Key note address to Philadelphia Urological Society. Jefferson School of Medicine, Philadelphia, PA, November 29, 2010.


  129. Who should be screened for prostate cancer? NYU School of Medicine: Surgical, Pharmacological and Technological Advances in Adult and Pediatric Urology State of the Art. December 10, 2010.


  130. Reducing the Harms of PSA Screening. Advances in Prostate Cancer: Georgetown University Hotel & Conference Center in Washington, DC. April 8 – 9, 2011.


  131. Reducing the Harms of PSA Screening. Grand Rounds at the Malizia Clinic in Atlanta, Georgia. April 30, 2011


  132. Active Surveillance for Prostate Cancer. Advanced Course on Prostate Cancer Management. Johns Hopkins Hospital, July 28, 2011.


  133. Active Surveillance for Prostate Cancer. Cancer Center Grand Rounds. Johns Hopkins Hospital, October 28, 2011.


  134. Reducing the Harms of Prostate Cancer Screening. New Perspectives on Prostate Cancer Symposium. Washington Adventist Hospital. Bethesda, MD, November 4, 2011.


  135. Eligibility and Inclusion for Active Surveillance: Tumor and Patient Metrics. NIH State of the Science Conference. NIH (Bethesda MD), December 5, 2011.


  136. The Prostate Cancer Screening Controversy. Epidemiology in Evidence Based Policy. Bloomberg School of Public Health. June 21, 2012.

 



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287